Paysign Inc. (PAYS)
NASDAQ (CM) NASDAQ (CM) Primary 
CXA 
Paysign, Inc. (PAYS) Q1 2025 Earnings Call Transcript
Paysign, Inc. (NASDAQ:PAYS ) Q1 2025 Earnings Conference Call May 6, 2025 5:00 PM ET Company Participants Mark Newcomer - President & Chief Executive Officer Jeff Baker - Chief Financial Officer Conference Call Participants Operator Good afternoon. My name is Chelsea, and I will be your conference operator today.
Paysign, Inc. (PAYS) Q4 2024 Earnings Call Transcript
Paysign, Inc. (NASDAQ:PAYS ) Q4 2024 Earnings Conference Call March 25, 2025 5:00 PM ET Company Participants Mark Newcomer - President and CEO Jeff Baker - CFO Matt Turner - President, Patient Affordability Matt Lanford - CPO Conference Call Participants Jacob Stephan - Lake Street Capital Markets Gary Prestopino - Barrington Research Peter Heckmann - D.A. Davidson Operator Good afternoon.
Paysign: Shifting Revenue Mix, Falling Stock, Compelling Opportunity
Paysign, Inc. is a small healthcare-focused Fintech company excelling in the $500M Patient Affordability market, with 230% revenue growth in its Pharma segment over the past four quarters. Despite a 40% stock decline in six months, Paysign's strong fundamentals and innovative solutions present a compelling investment opportunity with a fair value estimate of $3.33 per share. Paysign's strategic focus on Plasma and Patient Affordability programs, vertical integration, and innovation has driven significant growth and improved margins, funded entirely through organic cash flow.
Paysign Is A Leader In Fintech Healthcare Payments With Durable Profitable Growth
Paysign is a promising microcap payment processing company with a projected 42% annualized return, potentially reaching $19/share by 2030 from $3.30/share today. The company excels in two primary sectors: plasma payment processing and pharma patient affordability, both offering significant growth and high gross margins. PAYS's plasma business boasts a 40% market share with steady 10-15% annual growth, while the pharma segment is expected to surpass plasma with rapid expansion.
Paysign, Inc. (PAYS) Q3 2024 Earnings Call Transcript
Paysign, Inc. (NASDAQ:PAYS ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Mark Newcomer - President and CEO Jeff Baker - CFO Matt Turner - President, Patient Affordability Conference Call Participants Pete Heckmann - D.A. Davidson Gary Prestopino - Barrington Research Jon Hickman - Ladenburg Thalmann Operator Good afternoon.
Is Paysign (PAYS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Paysign (PAYS) Stock Outpacing Its Business Services Peers This Year?
Here is how Paysign, Inc. (PAYS) and Recruit Holdings Co., Ltd. (RCRRF) have performed compared to their sector so far this year.
Is Paysign (PAYS) Outperforming Other Business Services Stocks This Year?
Here is how Paysign, Inc. (PAYS) and Recruit Holdings Co., Ltd. (RCRRF) have performed compared to their sector so far this year.
Paysign: The Return Of The King Of Medical Fintech
Niche Focus: Paysign specializes in healthcare payment solutions, primarily in plasma donor compensation and patient affordability programs. Revenue Growth: Significant growth in the patient affordability segment is now a substantial part of total revenue. Financial Resilience: The company has shown strong revenue and margin recovery post-pandemic, with promising future growth.
Paysign, Inc. (PAYS) Q2 2024 Earnings Call Transcript
Paysign, Inc. (NASDAQ:PAYS ) Q2 2024 Earnings Conference Call July 31, 2024 5:00 PM ET Company Participants Mark Newcomer - President and CEO Jeff Baker - CFO Matt Turner - President of Patient Affordability Conference Call Participants Gary Prestopino - Barrington Research Operator Good afternoon. My name is Kevin, and I'll be your conference operator today.
